Emami Effort For Zandu Shares Reaches Indian High Court
This article was originally published in PharmAsia News
Executive Summary
One set of Zandu Pharmaceuticals promoters has petitioned the Bombay High Court to block Emami's effort to buy shares of the company from other Zandu promoters. The Parikh family based in Mumbai took the action against the Vaidyas group, but Zandu's chairman is trying to iron out the dispute. Y.P. Trevidi said he has asked both parties to resolve their differences out of court. The Parikhs, who own nearly a 25 percent stake in Zandu, filed the court action after failing to obtain a stay of Emami's acquisition offer, claiming they have the right of first refusal. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.